What is SENDO?

SENDO is a no-profit academic research organization coordinating a network of scientists and clinicians of international reputation dedicated to anticancer drug development.

SENDO promotes and supports innovative interdisciplinary anticancer drug research and stimulates interaction with industry in the early stages of drug development.


SENDO has its own portfolio of experimental projects and early clinical trials, but it can also provide pharmaceutical and biotechnology companies with access to top level research expertise and state-of-the art facilities.

SENDO draws on existing preclinical and clinical research in different areas to foster scientific partnerships between academic scientists and industry.


SENDO is currently a Foundation operating through a network of Core, Participating and Affiliate Members in Italy, Switzerland and Spain.


The Founding Members of SENDO are: 
Natale Cascinelli, Franco Cavalli, Alberto Costa, Maurizio D’Incalci, Silvio Garattini, Luca Gianni, Raffaella Giavazzi, Silvia Marsoni, Graziella Pratesi, Cristiana Sessa, Umberto Veronesi.

The Participating Members are: José Baselga and the Fondo Edo Tempia.

	Franco Cavalli M.D. President	Silvia Marsoni M.D. Director
Cristiana Sessa M.D. Clinical Coordinator	Luca Gianni M.D. Clinical Pharmacology Coordinator	Maurizio D'Incalci M.D. Preclinical Coordinator	Alberto Costa M.D. Tresaurer